This site is intended for health professionals only

Published on 10 June 2008

Share this story:
Twitter
LinkedIn

GSK acquires Sirtris

teaser

GlaxoSmithKline (GSK) announced today that it has completed its acquisition of Sirtris Pharmaceuticals Inc for approximately $720 million (EUR465 million) through a cash tender offer of $22.50 (EUR14.50) per share.

Through the acquisition of Sirtris, GSK has significantly enhanced its metabolic, neurology, immunology and inflammation research efforts by establishing a presence in the field of sirtuins, a recently discovered class of enzymes that is believed to be involved in the ageing process.

Sirtris will become part of GSK’s Drug Discovery organisation, while continuing to operate from laboratories in Cambridge, Massachusetts as an autonomous drug discovery unit.

GSK



Most read




Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine
Share this story:
Twitter
LinkedIn